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Background: Members of the inhibitor of DNA-binding (ID) family of helix-loop-helix proteins have been causally
implicated in the pathogenesis of several types of B-cell lineage malignancy, either on the basis of mutation or by
altered expression. B-cell chronic lymphocytic leukemia encompasses a heterogeneous group of disorders and is
the commonest leukaemia type in the Western world. In this study, we have investigated the pathobiological
functions of the ID2 and ID3 proteins in this disease with an emphasis on their role in regulating leukemic cell
death/survival.
Methods: Bioinformatics analysis of microarray gene expression data was used to investigate expression of ID2/ID3
in leukemic versus normal B cells, their association with clinical course of disease and molecular sub-type and to
reconstruct a gene regulatory network using the ‘maximum information coefficient’ (MIC) for target gene inference.
In vitro cultured primary leukemia cells, either in isolation or co-cultured with accessory vascular endothelial cells,
were used to investigate ID2/ID3 protein expression by western blotting and to assess the cytotoxic response of
different drugs (fludarabine, chlorambucil, ethacrynic acid) by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide assay. ID2/ID3 protein levels in primary leukemia cells and in MEC1 cells were manipulated by transduction
with siRNA reagents.
Results: Datamining showed that the expression profiles of ID2 and ID3 are associated with distinct pathobiological
features of disease and implicated both genes in regulating cell death/survival by targeting multiple non-overlapping
sets of apoptosis effecter genes. Consistent with microarray data, the overall pattern of ID2/ID3 protein expression
in relation to cell death/survival responses of primary leukemia cells was suggestive of a pro-survival function for
both ID proteins. This was confirmed by siRNA knock-down experiments in MEC1 cells and in primary leukemia
cells, but with variability in the dependence of leukemic cells from different patients on ID protein expression for
cell survival. Vascular endothelial cells rescued leukemia cells from spontaneous and cytotoxic drug-induced cell
death at least in part, via an ID protein-coupled redox-dependent mechanism.
Conclusions: Our study provides evidence for a pro-survival function of the ID2/ID3 proteins in chronic lymphocytic
leukemia cells and also highlights these proteins as potential determinants of the pathobiology of this disorder.
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The ‘Inhibitor of DNA-binding’ (ID) family of helix-
loop-helix proteins function as key regulators of lineage
specification and cell fate determination in Metazoa
[1-3]. In mammals, there are four ID family members
(ID1-ID4) that function by heterodimerising with and
antagonising the activities of several classes of transcrip-
tion factor. The E-protein family of basic helix-loop-
helix transcription factors (E2A/TCF3, E2-2/TCF4 and
HEB/TCF12) are the best characterised ID protein targets
[1-4]. In hematopoietic cells, individual ID proteins per-
form distinct, but overlapping functions in a lineage- and
differentiation-stage-specific manner [4-7]. ID proteins
have also been causally implicated in the pathogenesis of
leukemias and lymphomas; as in many solid tumour types,
ID-mediated tumourigenesis is coupled to various onco-
gene/tumour suppressor pathways in hematopoietic cells
[6]. Compelling evidence from loss- and gain-of-function
studies in transgenic mice and cell line models supports a
role for ID proteins in hematopoietic malignancies.
Individual ID proteins have been ascribed either an ‘onco-
gene’ or ‘tumour suppressor’ function in primary human
hematopoietic malignancies on the basis of expression
level, mutational pattern and functional properties. For ex-
ample, ID1 is a common downstream target of oncogenic
tyrosine kinases, exemplified by BCR-ABL in chronic
myeloid leukaemia, driving cell proliferation, survival and
invasiveness [6]. High ID1 expression is also associated
with a poor-prognosis subgroup of acute myeloid leukae-
mia [8]. Deregulated expression of ID2 is a consistent
feature of Hodgkin’s lymphoma and appears to function in
concert with ABF-1 in sequestering E2A and probably also
PAX5 to augment the B-cell-specific gene regulatory
programme in Hodgkin’s-Reed/Sternberg cells [9,10]. In
Burkitt lymphoma by contrast, the function of the ID3
protein is recurrently inactivated through the acquisition
of missense mutations in the ID3 gene, predominantly af-
fecting the helix-loop-helix dimerisation domain [11-13].
The ID4 gene similarly behaves as a tumour suppressor
through epigenetic silencing in most cases of acute mye-
loid leukemia [14], while in a sub-group of B-cell pre-
cursor acute lymphoblastic leukemia, expression of the
ID4 gene is deregulated by the recurrent t(6;14)(p22;
q32) chromosomal translocation [15,16].
B-cell chronic lymphocytic leukemia (CLL) is the most
prevalent type of leukemia in the Western world and it
manifests as a clonal expansion of CD5+, CD19+, CD23+
B cells [17,18]. In this leukemia type, the status of only
the ID4 family member has been evaluated in detail. In
the Eμ-TCL1 mouse model of CLL, loss of an ID4 allele
leads to more aggressive disease while hemizygous loss
of ID4 in nontransformed TCL-1-positive B cells enhances
cell proliferation [19]. These findings, together with the
observation that ID4 mRNA and protein expression isuniversally silenced in primary human CLL [14], strongly
implicate ID4 as a tumour suppressor in this disease [19].
For the ID3 family member, microarray gene expression
profiling data has shown that the expression of this gene
is deregulated in CLL. An analysis of published microarray
datasets of Zheng and colleagues [20] reveals a four-fold
upregulation of ID3 gene expression in CLL compared to
normal CD5+ B-cells. An independent study [21] showed
that ID3 is among the most significantly overexpressed
genes in a multivariate gene expression analysis compar-
ing CLL with normal CD19+ B-cells, consistent with a po-
tential role in CLL pathogenesis.
In addition to the various roles ascribed to individual
ID proteins in regulating cell cycle/cell growth, differen-
tiation, invasiveness, angiogenesis and metastasis in tu-
mours of diverse histological origin, these proteins have
also been widely documented to play a key role in regu-
lating cell survival [1-4]. However, the behavior of indi-
vidual ID proteins in functioning as either positive or
negative regulators of cell viability is highly cell type-
dependent, as illustrated by their contrasting functions
in mediating cell survival or cell death in different solid
tumour types in response to cytotoxic drugs [22-24]
(and references therein). Since the primary phenotypic
‘defect’ in CLL cells is their impaired ability to undergo
programmed cell death, and this has major implications
for cytotoxic drug therapy [17,18], it was pertinent to
determine whether ID proteins perform a functional
role in regulating cell survival in this leukemia, particu-
larly in response to cytotoxic drug treatment. We report
here that the ID2 and ID3 proteins impart pro-survival
functions in CLL cells cultured in vitro. In a more
physiologically-relevant in vitro co-culture system, vascu-
lar endothelial cells rescue CLL cells from spontaneous
and drug-induced cell death via an ID protein-coupled
redox-dependent mechanism.
Results
Datamining of ID2 and ID3 microarray gene expression
data in CLL
We initially extended previous findings from microarray
data that reported up-regulation of ID3 gene expression
in CLL [20,21] by performing a systematic meta-analysis
of microarray gene expression data, comparing relative
levels of ID2 and ID3 in CLL versus normal B cells. In
this and subsequent stages of our study, we confined the
analysis to these two ID genes/proteins since previous
studies have shown that ID4 expression is very low in pri-
mary CLL [14,19] and in preliminary analysis we found
that ID1 protein expression is undetectable by western
blotting in CLL cells. As shown in Figure 1, ID2 expres-
sion was down-regulated in CLL compared with normal B
cells in five of six datasets analysed, with two of the five
datasets showing a highly statistically significant difference
Figure 1 Meta-analysis of microarray data comparing ID2/ID3 gene expression in CLL with normal B cells. For each dataset (identified by
NCBI Gene Expression Omnibus GSE number), boxplot profiles are shown comparing normal B cells (open boxes) with CLL cells (shaded boxes).
P values for the significance of difference in mean expression of the pair-wise comparisons were corrected for false discovery rate [51]. P values
<0.05 are highlighted in bold-face. Log2 fold-change values (FC) are also given for each pair-wise comparison.
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found to be up-regulated in CLL compared with normal B
cells in all seven datasets analysed (Figure 1), consistent
with previous studies [20,21]; in five datasets, the level of
ID3 up-regulation was statistically significant. Notably, the
expression level of both ID2 and ID3 in CLL cells was
extremely heterogeneous, extending over a wide range in
each dataset.
We next analysed the relation between ID gene expres-
sion and clinical outcome in CLL using two independent
cohort datasets for which patient annotation data is
available in the public domain. As shown in Figure 2, high
ID2 expression was significantly associated with a more
favourable disease course in terms of an overall longer
time interval between initial sampling to first treatment
for both cohorts. This pattern was reflected by the longer
overall survival time for ID2-high patients (Figure 2C).
No significant relation between ID3 expression and
these clinical end-points was observed with either data-
set (Additional file 1: Figure S1).
Recently, Friedman et al. [25] defined seven distinct
molecular sub-types of CLL on the basis of unsupervised
clustering of gene expression microarray data compiled
from 15 datasets representing 893 unique CLLs. To deter-
mine whether differences in ID2/ID3 expression patternare associated with distinct molecular sub-types in CLL,
we performed a similar unsupervised consensus clustering
analysis of 871 CLLs compiled from 14 microarray data-
sets available in the public domain (see Materials and
methods). As shown in Additional file 2: Figure S2, con-
sensus clustering defined seven as the optimum number
of cluster groups in this combined, 871 sample dataset.
The gene signatures defining each of these cluster groups
mapped onto an overlapping set of pathways and onco-
genic signatures (Additional file 3: Table S1; Additional
file 4: Table S2) similar to those reported previously
[25]. Figure 3 shows the gene expression profiles of ID2
and ID3 across the seven cluster groups. There were sig-
nificant differences in ID2/ID3 expression levels amongst
the different cluster groups. ID2 was most significantly
up-regulated in cluster group 4 while ID3 was most sig-
nificantly up-regulated in cluster group 1 (Figure 3 and
see Additional file 3: Table S1; Additional file 4: Table S2).
To gain insight into the biological functions of the ID2
and ID3 proteins in CLL, we employed an unsupervised
reverse engineering of gene regulatory networks approach
by determining pair-wise statistical dependences between
expression of ID2/ID3 and all other genes in the com-
bined, 871 sample dataset (above). For this, we used the
Maximum Information Coefficient (MIC) algorithm [26]
Figure 2 Kaplan-Meier plots showing the relation between ID2 expression and clinical outcome in CLL. A: analysis of time to first
treatment for GSE39671 dataset; B: analysis of time to first treatment for GSE22762 dataset; C: analysis of survival time for GSE22762 dataset. For
each dataset, patients were grouped according to high (red line) and low (blue line) ID2 expression. The significance of the difference in clinical
end-point between high and low ID2 expression patient groups was determined by log rank test.
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perform more commonly used metrics such as linear re-
gression and mutual information [26,27]. MIC analysis
identified 678 (ID2) and 517 (ID3) regulatory interac-
tions with unique genes (Additional file 5: Table S3)
with only 21 genes in common. This mutual exclusivity
of MIC-inferred regulatory interactions of the two ID
genes was highly statistically significant (P <0.001 by
hypergeometric distribution test). Despite this lack of
overlap, the lists of MIC-inferred ‘target’ genes of the
two ID proteins were both over-represented in many of
the same Gene Ontology biological processes and path-
ways (Additional file 6: Table S4), in accord with the
known functional properties of these ID proteins [1-3].
Several of these pathways (eg apoptosis, TGF-alphasignalling, oxidative stress, angiogenesis, VEGF signal-
ling, p53 pathway) are known to play a key role in the
pathogenesis of CLL [18] (and references therein). We
focussed on apoptosis as the top-ranked pathway and
second-ranked Gene Ontology term for both ID genes
(Additional file 6: Table S4). Two additional apoptosis
pathways, oxidative stress response and the p53 pathway
were also shared by the MIC-inferred gene lists of ID2
and ID3. Figure 4 shows a network graph view of the in-
ferred regulatory interactions between ID2/ID3 and their
apoptosis ‘target’ genes, compiled from the gene lists that
overlap with the three apoptosis pathways (Additional
file 6: Table S4). The MIC-inferred apoptosis genes com-
prise both positive and negative regulators of cell death.
The network in Figure 4 has been expanded to include
Figure 3 Boxplot profile of ID2 and ID3 expression in the seven molecular sub-types of CLL identified by consensus clustering. For
each molecular sub-type (clusters 1–7), the distribution of relative ID2/ID3 expression values is shown together with the log2 fold-change (FC) and
significance level of the difference between the mean expression for the sub-type compared to all other sub-types. Significant differences that
indicate over- or under-expression of Id genes in individual sub-types are highlighted in bold-face. P values were corrected for false discovery
rate [51].
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regulatory interactions [29] and reveals a high degree of
inter-connectivity between the mutually exclusive MIC-
inferred ID2 and ID3 putative ‘target’ genes. Collectively,
these data imply a key role for both ID2 and ID3 in regu-
lating cell death/survival in CLL, most likely be targeting
multiple independent sets of target genes that are shared
by the same pathways.
Expression of ID proteins in primary CLL and correlation
with in vitro drug sensitivity
To validate and extend the preceding bioinformatics data,
we initially analysed the expression of the ID2 and ID3
proteins in a series of 14 CLL (Additional file 7: Table S5)
for which in vitro toxicity data was obtained for three
different drugs: fludarabine, chlorambucil and ethacrynic
acid. The first two of these drugs are widely used as part
of standard chemotherapy for CLL whilst ethacrynic acid
displays potent and specific in vitro cytotoxicity against
CLL cells through inhibition of the Wnt/β-catenin signal-
ling pathway [30]. Wnt/β-catenin signalling is reportedly a
key regulator of ID gene expression [2,3] and at least forID2, components of this pathway were significantly over-
represented in the list of MIC-inferred regulatory interac-
tions for ID2 (see Additional file 6: Table S4). The results
of western blotting analysis of the 14 CLL are shown in
Figure 5A (and see Additional file 8: Figure S3), and, in
Figure 5B, the normalised expression levels of ID2 and
ID3 are displayed graphically together with IC50 values for
each of the three drugs. Densitometric quantification of
the western blotting data is shown in Additional file 9:
Figure S4. The most obvious observation from these data
is the extreme heterogeneity in ID protein expression
pattern amongst different CLL samples, consistent with
the microarray data (see Figure 1). There was no signifi-
cant correlation between the expression levels of the two
ID proteins (P = 0.39; Pearson’s correlation). However, as
shown in Figure 6 for fludarabine and in Figure 7 for
chlorambucil, while there was no significant correlation
between ID2/ID3 expression and drug IC50 values by
Pearson’s analysis, those CLLs expressing the lowest 25th
percentile range of ID3 (but not of ID2) protein were sig-
nificantly more resistant than other CLLs to both drugs.
By contrast, a similar analysis of cell death, in the absence
Figure 4 Network graph showing interactions between ID2 and ID3 and their MIC-inferred ‘target’ genes regulating cell death.
MIC-inferred apoptosis target genes, denoted by green nodes connected to ID2/ID3 by blue edges, were compiled from apoptosis pathway
target genes in Additional file 6: Table S4. Green edges define protein-protein interactions, curated from the String database [28]. Pink edges
denote literature-validated regulatory interactions mined from the UniHI database [29] that have been expanded to include first-neighbour
interactions with additional targets as either pink nodes (not MIC-inferred target genes) or as grey (ID3) or white (ID2) MIC-inferred target genes
listed in Additional file 5: Table S3. A Cytoscape network graph circle layout is shown.
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highest 75th percentile range of ID3 (but again, not of
ID2) were significantly more resistant than other CLLs to
‘spontaneous’ cell death (Figure 8).
Changes in ID2 and ID3 protein expression pattern
following in vitro drug treatment
In understanding how levels of ID2/ID3 protein impact on
the in vitro drug response, it was important to determine
whether the expression pattern of these proteins under-
goes any change following drug treatment. As shown by
the heat-map representation of time-course western blot
experiments in Figure 9, both ID proteins displayed dy-
namic changes in expression, with each drug eliciting a
distinct pattern of ID protein expression. The expression
dynamics of ID2/ID3 were extremely heterogeneous with
no two CLLs displaying an identical pattern. However,
closer inspection reveals some suggestive trends in the IDprotein expression dynamics in the more drug-resistant
CLLs in response to all three drugs. In Figure 9, the CLLs
are arranged in ranked order of decreasing IC50 value (de-
creasing drug resistance) for each drug.
In five of the six CLLs examined, there was either a net
down-regulation or else a very modest change in expres-
sion of ID2 following 24 hrs of fludarabine treatment.
CLL06, which was the most resistant to this drug (IC50 =
18 μM - see Figure 5B), was exceptional in displaying a
transient peak of increased expression at 4-8 hrs. CLL06,
together with the second most fludarabine-resistant sam-
ple in the series, CLL13, (IC50 = 11 μM) also displayed the
highest sustained increase in expression of ID3. The third
most fludarabine-resistant sample (CLL17; IC50 = 4.5 μM)
similarly exhibited a sustained, although less pronounced
increase in ID3 expression. In the remaining (more
fludarabine-sensitive) CLLs, there was either a net down-
regulation or else very little change in ID2/ID3 expression
Figure 5 Analysis of ID protein expression levels in primary CLL. (A) Western blotting analysis of ID2 and ID3 expression was performed in
two separate experiments depicted in the two panels shown. CLL10 and CLL11 samples were included in both experiments to monitor internal
consistency. Immunoblots were re-probed with anti-GAPDH antibody as a control for protein loading. The original western blot images that were
used to compile Figure 5A are shown in Additional file 8: Figure S3. (B) Protein bands were quantified by densitometric scanning and normalized
to the GAPDH loading control and, for each ID protein, expressed as fold-change (relative expression level) relative to the CLL sample with the
lowest expression level on the left blot (CLL08 for ID2 and CLL17 for ID3). Densitometric quantification of the western blotting data is shown in
Additional file 9: Figure S4. CLL samples are shown rank-ordered by increasing levels of ID3 expression. In vitro IC50 values were determined
following 72 hrs of treatment for each CLL sample; ND: not determined.
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tially expressed low levels of ID3 (including the two
fludarabine-resistant samples, CLL06 and CLL13 – see
Figure 5B) were characterised by a sustained pattern of in-
creased ID3 expression in response to fludarabine while
those CLLs expressing high levels of ID3 before drug
treatment exhibited the most down-regulation of ID3 ex-
pression. Thus, the low ID3 expression associated with
fludarabine-resistance before drug treatment (Figure 6),
manifested as increased expression of ID3 on exposure to
this drug. A similar pattern was observed for ID3 in rela-
tion to chlorambucil response (Figure 9); the three more
resistant CLLs (CLL13, CLL06, CLL12) all displayed a
sustained increase of ID3. However, two of the more
chlorambucil-sensitive CLLs (CLL11, CLL08), in addition
to CLL13, showed sustained up-regulation of ID2 in
response to chlorambucil, although we note that both
CLL11 and CLL08 exhibited the most pronounced down-
regulation of ID3 in response to this drug (Figure 9).
Ethacrynic acid treatment resulted in up-regulation of
ID2/ID3 in four of the six CLL samples (Figure 9). How-
ever, as with fludarabine, the most marked up-regulation
was seen in those CLLs that were most resistant to thisdrug: CLL13 (ID2) and CLL11, CLL12 (ID3). The
remaining more ethacrynic acid-sensitive CLLs (CLL06,
CLL08, CLL17) all displayed a strong down-regulation
in ID3 expression and only minor changes in expression
of ID2.
Collectively, the above time-course ID protein expres-
sion data suggest a trend in which for each drug, the more
drug-resistant CLLs were associated with a pattern of
marked up-regulation of ID3 and to a lesser extent of ID2.
siRNA-mediated knock-down of ID2 and ID3 expression
reduces survival of CLL cells
The observed pattern of drug-induced expression changes
of ID proteins in CLL, in which down-regulation was as-
sociated with cell death in more drug-sensitive CLLs and
up-regulation with cell survival in the more drug-resistant
CLLs is consistent with the data showing high ID3 expres-
sion in CLLs that were more resistant to spontaneous cell
death (Figure 8) and is suggestive of a pro-survival func-
tion for the ID proteins in this tumour type. To directly
evaluate this, we initially employed MEC1 cells [31] as a
cell line model of CLL. As shown in Figure 10A (and
Additional file 10: Figure S5), following transduction of
Figure 6 Relation between in vitro fludarabine resistance and ID protein expression levels in 14 CLL samples. Data for relative ID
expression levels and IC50 values are given in Figure 5B in the main manuscript. The left-hand plots show linear regression analysis where samples
are coded according to ID protein expression range (open triangles: lowest 25th percentile; open squares: highest 75th percentile; solid diamonds:
remaining samples). The right-hand plots show a comparison of ID protein expression levels between samples grouped according to percentile
range of ID protein expression. Significant (<0.05) P values, calculated by Student’s t-test, are indicated in bold-face.
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ing each ID mRNA, a single cell pool of MEC1 cells was
identified for each ID gene that displayed reduced levels
of expression of ID protein (ID2R and ID3Y). These
cells were expanded alongside the control siRNA-
transduced cells (Figure 10A) and examined for in vitro
drug sensitivity. Since MEC1 cells are known to be re-
calcitrant to fludarabine-induced cell death [32], the im-
pact of either ID2 or ID3 knock-down on chlorambucil
and ethacrynic acid-induced cell death was evaluated.
As shown in Figure 10B (and Additional file 10: Figure
S5), even in the absence of drug, the viability of ID2R-
ID3Y-transduced cells was significantly less than control
cells. Thus, loss of either ID2 or ID3 expression leads to
extensive cell death. Following chlorambucil/ethacrynic
acid treatment, there was a commensurate further loss
of viability of ID2R- ID3Y-transduced cells, compared
with control cells (Figure 10B).
This analysis was extended to four different primary
CLLs by using siRNA reagents to directly knock-down
the expression of ID2 or ID3. As shown in Figure 10C
(and in Additional file 10: Figure S5), treatment of CLL
cells with the ID2 or ID3 siRNAs led to a variable reduc-
tion in levels of the respective proteins, relative tocontrol siRNA. Since the preceeding analysis showed
that fludarabine elicited the most distinctive pattern of
association between drug-induced ID2/ID3 expression
and fludarabine resistance (Figure 9), we focussed on
this drug in analysing the effects of ID2/ID3 knock-
down. Figure 10D shows that even in the absence of flu-
darabine, in three out of the four CLL samples exam-
ined, knockdown of ID2 and ID3 reduced cell survival
significantly. In CLL18, knockdown of ID2 or ID3 had
no significant effect on cell viability in the absence of
fludarabine treatment (Figure 10D). Of the four CLLs
investigated, this CLL was the most resistant to fludara-
bine (IC50 = 9.0 μM). Following treatment of CLL18
cells with fludarabine, cell viability was reduced by 8.8%
in the control sample compared to 21% in the ID2
knock-down and to 24% in the ID3 knockdown sample.
Although the magnitude of this siRNA effect only reached
statistical significance in the latter (Figure 10D), these data
suggest that in this more fludarabine-resistant CLL, in
which the overall extent of fludarabine-induced cell death
was less than in the three other CLLs, loss of ID protein
function demonstrably potentiates the fludarabine cyto-
toxic response. siRNA-mediated knock-down of ID2 and
ID3 led to a modest (not statistically significant) reduction
Figure 7 Relation between in vitro chlorambucil resistance and ID protein expression levels in 14 CLL samples. Data for relative ID
expression levels and IC50 values are given in Figure 5B in the main manuscript. The left-hand plots show linear regression analysis where samples
are coded according to ID protein expression range (open triangles: lowest 25th percentile; open squares: highest 75th percentile; solid diamonds:
remaining samples). The right-hand plots show a comparison of ID protein expression levels between samples grouped according to percentile
range of ID protein expression. Significant (<0.05) P values, calculated by Student’s t-test, are indicated in bold-face.
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cells following fludarabine treatment in two of the other
CLLs (CLL14, CLL19).
Taken together, these observations in primary CLL
cells are consistent with the MEC1 cell line stable
knock-down data in showing that the ID2 and ID3 pro-
teins perform a pro-survival function in CLL.
Vascular endothelial cells rescue CLL cells from
spontaneous and drug-induced cell death via an ID
protein-coupled redox-dependent mechanism
Recent studies have shown that stromal (accessory) cell-
mediated protection of CLL cells from both spontaneous
and drug-induced cell death relies on the release of cyst-
eine, an important precursor in glutathione (GSH) synthe-
sis, into the microenvironment and subsequent uptake by
CLL cells [33]. Reduced GSH levels are associated with
oxidative stress leading to cell death. Since several stud-
ies have implicated ID proteins, specifically ID2 and
ID3, in the mediation and control of cellular responses
to oxidative stress [34-36] and our own data showed en-
richment of components of the oxidative stress signal-
ling pathway in MIC-inferred ‘targets’ of ID2/ID3 (see
Additional file 6: Table S4), we reasoned that the pro-
survival functions of ID2/ID3 in CLL cells might play a
role in mediating rescue from cell death by accessoryadherent cells. To investigate this, we employed a co-
culture system with human umbilical vein vascular
endothelial cells (HUVEC) that has previously been shown
to rescue CLL cells from spontaneous and fludarabine-
induce cell death [37]. Consistent with previous data [37],
co-culture with HUVEC rescued CLL cells from both spon-
taneous (Figure 11A) and fludarabine-induced (Figure 11B)
cell death. In addition, we extended these observations
to show that HUVEC co-culture also rescued CLL cells
from cell death induced by chlorambucil and ethacrynic
acid (Figure 11B). To determine whether the protective
effect from fludarabine-induced cell death is mediated
by direct cell-to-cell contact or by humoral factors,
CLL cells were grown in media that had been condi-
tioned by 48 hrs HUVEC-CLL co-culture (Figure 11C).
In this ‘double conditioned media’ (CM), the CLL
population maintained a significantly higher percentage
of viable cells after treatment with 15 μM fludarabine
than cells cultured in normal fresh medium. However,
this protective effect was significantly less than with
cells co-cultured directly with HUVEC (Figure 11C),
indicating that the pro-survival functions of HUVEC in
response to fludarabine are, as with rescue from spon-
taneous cell death [37], likely to be mediated by a
combination of both humoral and direct heterologous
cellular interactions.
Figure 8 Relation between resistance to in vitro spontaneous cell death and ID protein expression levels in 14 CLL samples. Relative
numbers of viable cells were determined from MTT assay data after 72 hrs culture; data points show the mean ± SEM. Data for relative ID expression
levels are given in Figure 5B in the main manuscript. The left-hand plots show linear regression analysis where samples are coded according to ID
protein expression range (open triangles: lowest 25th percentile; open squares: highest 75th percentile; solid diamonds: remaining samples). The
right-hand plots show a comparison of ID protein expression levels between samples grouped according to percentile range of ID protein expression.
Significant (<0.05) P values, calculated by Student’s t-test, are indicated in bold-face.
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role in mediating this protective effect, the GSH pathway
was inhibited by treatment with PEITC, a thiol conjugate
that depletes intracellular GSH levels [38] during HUVEC-
CLL co-cultures. As shown in Figure 12A & B (and see
Additional file 11: Figure S6; Additional file 12: Figure S7),
co-culture with HUVEC increased both ID2 and ID3 pro-
tein levels in two CLL samples examined, an effect which
correlated with rescue from spontaneous and fludarabine-
induced cell death. PEITC treatment partially overcame
the rescue from fludarabine-induced cell death imparted
by HUVEC co-culture, and this was accompanied by de-
creased ID2 and ID3 protein expression. Specifically,
For CLL12 (Figure 12A and see Additional file 11:
Figure S6) a comparison between the most relevant con-
trol of fludarabine-treated cells cultured on HUVECs
(lane 5) with the same cells treated additionally with
PEITC (lane 7) showed a clear reduction (approximately
two-fold) in both ID2 and ID3 in the latter (see densito-
metric data in Additional file 12: Figure S7). The same
comparison for CLL18 (lane 6 vs lane 7 in Figure 12B)
similarly revealed a small (albeit insignificant) reduction
in ID2, but the reduction in ID3 was very comparable to
that seen for CLL12. Hence, even for CLL18, which was
one of the most ‘extreme’, fludarabine-resistant samples,there was a reduction in expression of at least one of the
ID proteins following partial blockade of GSH signalling
in HUVEC co-cultures following treatment with fludara-
bine. To confirm that GSH release is a probable mecha-
nism through which HUVEC co-culture promotes CLL
survival and that it affects modulation of ID protein ex-
pression, CLL cells were treated with GSH or L-cysteine.
Consistent with the report of Zhang et al. [33] we found
that both compounds protect from spontaneous and
fludarabine-induced cell death (Figure 12C & D and see
Additional file 12: Figure S7). In addition, both GSH and
L-cysteine mimic the presence of HUVEC by commensu-
rately increasing ID2 and ID3 protein levels.
Discussion
Previous studies have shown that ID2 and ID3 are crucial
mediators of B-lymphocyte development and are also in-
volved in the regulation of B-cell viability (reviewed in
[4,39]), functioning to promote either B-cell death or B-
cell survival, depending on the particular context. In CLL,
our bioinformatics analysis showed that the expression
profiles of ID2 and ID3 are associated with distinct
pathobiological features of this disease. ID2 expression
was down-regulated in CLL versus normal B cells in
most microarray datasets. Consistent with this, high
Figure 9 ID2 and ID3 protein expression patterns in response to in vitro drug treatment. CLL cells from six patients were cultured in the
presence of varying concentrations of fludarabine, chlorambucil and ethacrynic acid for 24 hrs. The concentration of drugs were chosen for each
CLL, based on IC50 values (see Figure 5B) such that a significant fraction of viable cells remained after the 24 hrs drug treatment period. At the
indicated time points, ID2, ID3 and GAPDH (control) levels were analysed by western blotting. The bands were quantified by densitometric
scanning and normalized to the intensity of the loading control (GAPDH). The fold-change in expression, relative to the untreated control was
determined and, after log2-transformation was displayed as a heat map as shown. For each drug, CLL samples are shown rank-ordered by
decreasing IC50 value (decreasing drug resistance).
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clinical outcome. By contrast, ID3 expression was con-
sistently up-regulated in CLL versus normal B cells but
exhibited no significant association with clinical end-
points, at least when analysed in available datasets. Both
ID genes displayed a distinct expression profile amongst
the different molecular sub-types of CLL that have been
defined previously [25] and MIC analysis showed that
the two ID genes are coupled to gene regulatory networks
that are largely non-overlapping in CLL. However, gene
set and pathway enrichment analysis suggested that both
ID genes function in many of the same biological pro-
cesses and pathways by regulating the expression (directly
or indirectly) of a distinct set of target genes. This analysis
invoked regulation of apoptosis/cell death in which bothID genes play a major role in CLL. It should be noted that
because of the non-directional nature of MIC-inferred
regulatory interactions, not all of the genes identified by
MIC analysis are necessarily regulated by ID2/ID3 (rather
than vice versa). Nonetheless, given the large number of
apoptosis genes that were identified from pathway enrich-
ment analysis (see Figure 4), it is plausible that ID2 and
ID3 each regulate the expression of a sizable number of
genes (both pro- and anti-apoptotic) involved in cell sur-
vival of CLL.
Recent whole-genome and exome sequencing of CLL
has revealed that, in contrast to the reported high frequency
of recurrent ID3 mutations observed in Burkitt lymphoma
and (less commonly) in some other B-lymphoma types
[11-13], mutations in ID genes do not occur at a significant
Figure 10 ID2 and ID3 gene knockdown reduces survival of MEC1 cell line and primary CLL cells. (A) Western analysis of MEC1 cells
infected with lentiviruses encoding either a control siRNA sequence or encoding one of four siRNAs targeting different sequences in the ID2/ID3
mRNAs. The original western blot images are shown in Additional file 10: Figure S5. (B) MEC1 cells that were transduced with control siRNA
(open bars), ID2R-siRNA (light-shaded bars) or ID3Y-siRNA (dark-shaded bars) were incubated in the absence or presence of increasing concentrations
chlorambucil or ethacrynic acid for 48 hrs and cell viability was assessed by MTT assay. The mean ± SEM of three independent samples is shown.
(C) CLL cells from four patients were transfected with 60 nM negative control siRNA or with ID2/ID3 siRNA. 72 hrs post-transfection, cells were harvested
and analysed by western blotting. The original western blot images are shown in Additional file 10: Figure S5. (D) 1×106 cells from the four CLL
patients were transfected with 60 nM negative control siRNA (open bars) or with the same concentration of ID2 siRNA (light-shaded bars) or ID3 siRNA
(dark-shaded bars). 48 hrs post-transfection, the cells were incubated in the absence or presence of fludarabine (5 μM) for a further 24 hrs. Cell viability
was assessed by MTT assay and values were normalised to the untreated control siRNA sample. Data from the mean ± SEM from three independent
samples is shown.
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Figure 11 Human umbilical vein endothelial cells (HUVEC) protect CLL cells from spontaneous and drug-induced cell death. (A) CLL
cells from two patients were cultured alone or on a monolayer of HUVEC for three or seven days. Cell viability was assessed by MTT assay and
values were normalized to the uncultured control. Data are from the mean ± SEM of two CLL samples (CLL11 and CLL12) each analysed in
triplicate. (B) CLL cells from three patients (CLL07, top panel, CLL11, middle panel and CLL12, lower panel) were pre-cultured alone (broken line)
or on a HUVEC monolayer (solid line) for 24 hrs. The cells were then cultured under the same conditions in the absence or presence of two
different concentrations of fludarabine, chlorambucil or ethacrynic acid for a further 48 hrs. Cell viability was assessed by MTT assay and
values were normalized to the respective untreated control for each culture condition. Data are from the mean ± SEM of three independent
experiments. The statistical significance of differences in cell viability between control CLL and HUVEC-co- culture CLL is indicated by the P values
for each drug concentration. (C) Conditioned medium (CM) was harvested from a 48 hrs co-culture of CLL cells with HUVECs. CLL cells were
pre-cultured in either normal medium or in the CM medium or else on a monolayer of HUVEC for 18 hrs. The cells were then cultured under the
same conditions in the presence or absence of fludarabine (15 μM) for a further 48 hrs. Cell viability was assessed by MTT assay and values were
normalized to the untreated control. Data show the mean ± SEM from three independent samples.
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Figure 12 The effect of HUVEC co-culture and augmentation of CLL glutathione levels on fludarabine-induced cell death and ID2/ID3
protein expression. CLL12 (A) and CLL18 (B) cells were pre-cultured alone or on a monolayer of HUVEC for 24 hrs. The cells were then cultured
under the same conditions for a further 48 hrs in the absence or presence of fludarabine (20 μM). PEITC (5 μM for A, 20 μM for B) was added
during the last 5 hrs of culture. Cell viability was assessed by MTT assay and values were normalized to the uncultured control (T0). The data show
the mean ± SEM of three independent samples. Protein levels of ID2, ID3 and GAPDH were analyzed by western blotting. The original western
blot images are shown in Additional file 11: Figure S6. CLL cells from patient CLL12 (C) and CLL18 (D) were pre-cultured in the absence or
presence of GSH (2 mM for C, 4 mM for D) or L-cysteine (50 μM for C, 100 μM for D) for 24 hrs. The cells were then cultured for a further 48 hrs
in the absence or presence of fludarabine (20 μM). L-cysteine was added to the culture medium daily. Cell viability was assessed by MTT assay
and values were normalized to the uncultured control (T0). The data show the mean ± SEM of three independent samples. Protein levels of ID2,
ID3 and GAPDH were analyzed by western blotting. The original western blot images are shown in Additional file 11: Figure S6. Quantification of
western data by densitometric scanning is shown in Additional file 12: Figure S7.
Weiler et al. Molecular Cancer  (2015) 14:30 Page 14 of 20frequency in CLL [18] (and references therein). Indeed, of
the several hundred CLL cases so far sequenced in different
laboratories, only a single instance of a mutated ID gene
has so far been reported (a missense mutation - E48V) af-
fecting ID2 [40], the functional significance of which is un-
known. Consistent with the bioinformatics analysis (above),
our data show that, at the protein level, the expression of
ID2 and ID3 is extremely heterogeneous amongst different
CLLs and, from siRNA knock-down experiments, both pro-
teins appear to perform pro-survival functions in both
spontaneous and drug-induced cell death in this leukemic
cell type. Although based on a very small cohort of CLLsamples, we also observed a possible association between
low ID3 protein expression (before drug treatment) and
in vitro drug resistance for both fludarabine and chloram-
bucil. On exposure to these drugs, this was reflected by a
pattern of down-regulation of ID3 expression in the more
drug-sensitive and up-regulation in the most drug-resistant
samples, consistent with the pro-survival function of this
ID protein. Albeit with different kinetics, chlorambucil also
elicited down-regulation of at least one of the two ID pro-
teins in chlorambucil-sensitive CLLs and up-regulation of
both ID proteins in the CLL that was most resistant to this
drug. Finally, the drug, ethacrynic acid, which in contrast to
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inhibition of the Wnt/β-catenin signalling pathway [30] that
is also known to be a key regulator of ID gene expression
[2,3] (and was also inferred from pathway enrichment ana-
lysis of ID2 MIC ‘targets’ in CLL – see Additional file 6:
Table S4). Perhaps unsurprisingly, ethacrynic acid elicited
dramatic changes in ID2/ID3 protein expression that were
characterised by marked up-regulation of ID2/ID3 levels in
those CLLs that were the most resistant to this drug, again
consistent with a pro-survival function for the ID2/ID3 pro-
teins in the ethacrynic acid cytotoxic response.
We also noted a possible association between high ID3
protein levels and resistance to spontaneous cell death
in the absence of drug treatment, again consistent with a
pro-survival function for this ID protein, although this
observation should again be interpreted with caution
since the analysis was based on a very small cohort of
CLLs. However, these findings are in accord with pub-
lished microarray gene expression studies; datamining
reveals that ID3 mRNA levels are significantly higher in
the IGHV-mutated subset of CLL [41], that is reportedly
more resistant to in vitro spontaneous cell death, than
IGHV-unmutated CLLs [42]. Moreover, low ID3 mRNA
expression is part of a distinct gene expression signature
associated with ATM-mutated CLL [43]. ATM-mutated
CLL (low ID3) define a sub-group of patients with an un-
favourable clinical course [43] and IGHV-mutated CLL
(high ID3) define a more favourable prognostic sub-group
(reviewed in [44]).
Knock-down of ID2/ID3 expression dramatically re-
duced cell viability in the MEC1 cell line model. But as
with the ID expression data, the effect of siRNA knock-
down in primary CLL was heterogeneous. A statistically
significant effect of ID2/ID3 knock-down on cell viabil-
ity in the absence of fludarabine treatment was observed
in three of the four CLLs examined. The exception
(CLL18) expressed the lowest levels of ID2 and ID3,
consistent with the observed diminished effect of ID
knock-down in these cells. Following fludarabine treat-
ment, the effect of ID knock-down on cell viability was
even more heterogeneous, reaching statistical signifi-
cance in only one CLL, but with an appreciable effect in
a further two.
Recent studies have shown that expression of the E-
protein bHLH transcription factor, E2A/TCF3, that is
one of the key targets of ID proteins, is elevated relative
to normal B cell subsets in CLL and also promotes cell
survival [45]; E2A mRNA knock-down leads to reduced
CLL cell viability [45]. A similar effect of E2A mRNA
knock-down has also been described in prostate cancer
cells where it was shown to cause down-regulation of ID
gene expression [46]. Since we have shown that loss of
ID2/ID3 expression leads to loss of viability in CLL cells,
the cell death reported to accompany loss of E2Aexpression in CLL cells [45] may well be mediated via
loss of ‘downstream’ ID protein expression.
The interaction between CLL cells and the bone mar-
row/lymph node stromal cell environment in vivo is known
to profoundly affect CLL cell viability and drug sensitivity,
and this can be recapitulated in vitro by co-culture with
accessory bone marrow stromal cells [47] or with vascular
endothelial cells [37,48]. We found that depletion of GSH
using PEITC abrogated HUVEC-mediated rescue of CLL
cells from both spontaneous and fludarabine-induced cell
death, implicating a redox-dependent pro-survival mech-
anism imparted by HUVEC cells, similar to that reported
for bone marrow stromal cells [33]. Although off-target ef-
fects of PEITC, at the concentrations used in our study,
have not been noted in previous studies on CLL [33,38]
this cannot however be completely ruled out. Consistent
with recently published gene expression microarray data
[37], co-culture with HUVEC cells led to up-regulation of
ID2 and or ID3 protein expression in CLL cells, an affect
that was modulated by PEITC depletion of GSH or by dir-
ect addition of GSH or L-cysteine to an extent commen-
surate with rescue from cell death. These observations
are in accord with the pathway enrichment analysis of
MIC-inferred regulatory interactions (see Additional file 6:
Table S4) which identified the oxidative stress response as
a pathway shared by both ID2 and ID3. Although we did not
directly determine intracellular GSH levels in our study,
the role of GSH in survival of CLL (either in isolation or
co-culture with accessory cells) has previously been estab-
lished by other laboratories from direct measurement of
intracellular GSH [33]. It should be noted that the data in
this part of our investigation was based on analysis of only
two CLLs. However, given that these CLLs were quite dif-
ferent (one sensitive, the other highly resistant to fludara-
bine) and both gave broadly consistent results, the data
could be considered to be ‘representative’. With this caveat
in extrapolating the findings to CLL too generally, our data
support a model in which HUVEC co-culture imparts its
protective effect on CLL cells at least in part by increasing
intracellular GSH levels, which in turn leads to increased
expression of the redox-responsive pro-survival ID2 and
ID3 proteins.
Conclusions
In summary, we have undertaken a comprehensive data-
mining investigation of CLL using available gene expres-
sion microarray data to show that the expression profiles
of ID2 and ID3 are associated with distinct pathobiological
features of this disease and both are strongly implicated in
regulating cell death/survival in CLL cells. Experimental
evidence supported a pro-survival role for both ID pro-
teins in CLL and was extended to show that, in a more
physiologically-relevant in vitro co-culture system, vascu-
lar endothelial cells rescue CLL cells from spontaneous
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coupled redox-dependent mechanism. Future studies
might usefully explore the precise molecular mecha-
nisms through which ID proteins are involved in disease
pathogenesis and treatment response in CLL with a view
to identifying candidate targets for therapeutic interven-
tion in this disease.
Materials and methods
Ethics statement
The study protocol including consent procedures was ap-
proved by the UK local NHS Ethics Committee (protocol
reference: 08/H0302/90). Peripheral blood samples were
obtained from CLL patients, together with ‘anonymised’
patient data after informed written consent in accordance
with the principles expressed in the Declaration of Helsinki.
All records (including signed consent forms) were main-
tained in a secure database at the Ipswich Hospital NHS
Trust, Suffolk, UK.
Datamining of microarray gene expression data
For analysis of ID2/ID3 gene expression in CLL versus
normal B cells, normalized microarray gene expression
datasets were obtained from the NCBI Gene Expression
Omnibus database [49]. Samples representing normal B
and CLL cells were curated from each dataset and, after
log2 transformation of expression values, differential ex-
pression was analysed using the limma package [50] in
Bioconductor R. P values for the significance of differential
expression were corrected for false discovery rate [51].
Two microarray datasets with publicly available clinical
follow-up data were fRMA-normalised [52] and down-
loaded from InSilico DB [53]: GSE39671 [54] with annota-
tion data on time to first treatment for 130 patients, and
GSE22762 [55] with annotation data on both time to first
treatment and survival time for 107 patients. Kaplan-Meier
plots were constructed using GenePattern [56] by parti-
tioning samples according to ID gene expression into ID2/
ID3-high (upper 50%) and ID2/ID3-low (lower 50%) pa-
tient groups. The statistical significance of differences in
Kaplan-Meier plots was determined by log-rank test.
Consensus clustering analysis was performed essen-
tially as described previously [25] except that a compos-
ite dataset comprised of 871 CLLs from 14 individual
datasets (omitting GSE15777) was used. Briefly, CLL
samples from each dataset were curated in InSilico DB
[53] and the fRMA-normalised datasets were downloaded
and merged using the ‘COMBAT’ algorithm with the inSi-
licoMerging R/Bioconductor package [57]. The combined
dataset was marker center-normalized and analysed with
the ‘ConsensusClusterPlus’ package in R/Bioconductor
[58] using Euclidean distance and Ward2 agglomerative
methods with 1000 iterations. The optimum number of
cluster groups (seven) was ascertained from the delta areaplot where there was minimal relative decrease in the
consensus cumulative distribution function (CDF). Gene
signatures representing each cluster group (gene sets
significantly up-regulated in each cluster group) were gen-
erated using the GenePattern limma package [50,56] ap-
plying a Bonferroni-corrected P value threshold of 0.01
and were analysed for significant overlap with KEGG
pathway and Oncogenic signatures databases using the
GSEA on-line database [59].
To identify candidate target genes that are regulated by
ID2/ID3 in CLL, we employed the ‘maximal information-
based nonparametric exploration’ (MINE) statistics pack-
age in Bioconductor, R [26] to compute maximum
information coefficient (MIC) scores and other metrics
as a measure of the statistical dependency between expres-
sion of ID2/ID3 and all other genes in the composite 871
CLL microarray dataset (above). A threshold cut-off MIC
score corresponding to a Bonferroni-corrected P value
(calculated using 3×107 permutations) of 0.01 was applied
to identify the most statistically significant candidate ‘tar-
get’ genes. The resulting gene lists were analysed for over-
representation of Gene Ontology (biological process) and
pathway gene sets using the GeneCodis database [60].
Candidate apoptosis target genes were further investigated
for protein-protein interactions using the ‘String’ (v9.1)
database [28] and for literature-validated regulatory inter-
actions using the ‘Unified Human Interactome’ (UniHI)
database [29]. A network graph was constructed and
visualised using Cytoscape v2.8 [61].
CLL patients, cell isolation and culture conditions
Peripheral blood samples from 14 CLL patients were ob-
tained from patients attending the Hematology out-patient
clinic at Ipswich Hospital NHS Trust (Suffolk, UK). Pa-
tients were selected having a white cell count of >45×109/L
in order to ensure a high representation of CLL cells. Pa-
tient characteristics are listed in Additional file 7: Table S5.
Peripheral blood mononuclear cells were isolated by dens-
ity gradient centrifugation using Ficoll-Paque PLUS (GE
Healthcare, Little Chalfort, UK) according to the manu-
facturer’s protocol. The MEC1 cell line [31] (DMSZ,
Braunschweig, Germany) and primary CLL cells were
cultured in IMDM supplemented with 10% fetal bovine
serum (FBS) and 45 μg/ml gentamicin (all from PAA,
Pasching, Austria) at 37°C and 5% CO2 in a humidified
incubator. Primary CLL cells were seeded at a density of
1.5-5×106 cells/ml, while MEC1 cells were maintained
at a cell density between 0.5-1×106 cells/ml.
Human umbilical vein endothelial cells (HUVEC, TCS
Cellworks, Buckingham, UK) were cultured in human
large vessel endothelial cell growth medium (TCS Cell-
works) on poly-lysine-coated tissue culture flasks. For
co-culture experiments, HUVECs were seeded at 60%
density and incubated for 24 hrs before the medium was
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monolayer at 1.5×106 cells/ml in IMDM/10% FBS. Cells
were maintained under these co-culture conditions for
24 hrs, prior to drug addition and then cultured in the
presence of drugs for another 48 hrs. The ‘double condi-
tioned medium’ (CM), was harvested from a co-culture
of HUVEC and CLL cells after 48 hrs, filter-sterilized
and stored at 4°C until required. Glutathione (GSH),
Phenethyl-isothiocyanate (PEITC), L-cysteine, fludara-
bine, chlorambucil and ethacrynic acid were purchased
from Sigma-Aldrich (St-Louis, MO, USA).
Lentivirus production and infection of MEC1 cells
Lentiviral vectors encoding siRNA targeting either con-
trol or the ID2 and ID3 genes were purchased from Ap-
plied Biological Materials (ABM) Inc. (Richmond, BC,
Canada). The vector backbone (piLenti-siRNA-GFP) con-
tains convergent U6 and H1 promoters producing double-
stranded siRNA molecules. The sequences targeted by
these siRNAs were as follows:
ID2R-siRNA: 5’-TGTGGACGACCCGATGAGC-3’,
ID2Y-siRNA: 5’-ATCGACTACATCTTGGACCTG
CAGATCGC-3’,
ID2G-siRNA: 5’-CCCACTATTGTCAGCCTGC
ATCACCAGAG-3’,
ID2B-siRNA: 5’-TCTGAGTTAATGTCAAATGACA
GCAAAGC-3’,
ID3R-siRNA: 5’-ACTCAGCTTAGCCAGGTGGAAA
TCCTACA-3’,
ID3Y-siRNA: 5’-ATCGACTACATTCTCGACCTG
CAGGTAGT-3’,
ID3G-siRNA: 5’-ACCTTCCCATCCAGACAGCC
GAGCTCACT-3’,
ID3B-siRNA: 5’-CCGGAACTTGTCATCTCCAACG
ACAAAAG-3’,
Negative control siRNA: 5’-GGGTGAACTCACGTCA
GAA-3’.
The second generation packaging plasmids psPax2 and
pMD2.G were purchased from Addgene (deposited by
Prof. Didier Trono, Lausanne, Switzerland). Human em-
bryonic kidney (HEK 293 T) cells were cotransfected with
2 μg siRNA lentiviral expression vector together with
1.3 μg psPax2 and 0.7 μg pMD2.G using the calcium
phosphate method and then used for a 48 hr co-culture
with 5×105 MEC1 cells followed by selection for 14 days
with puromycin (1.5 μg/ml). Stable pools of transduced
MEC1 cells were then expanded in IMDM/10% FBS with-
out puromycin.
siRNA-mediated knock-down of ID protein expression
siRNA transfection of primary CLL cells was performed
using a HiPerfect transfection kit (Qiagen, Hilden,Germany), according to the manufacturer’s guidelines.
Briefly, 1×106 CLL cells were seeded in 200 μl IMDM/
10%FBS and transfected with 60nM siRNA (final con-
centration in 600 μl) and 5 μl HiPerfect transfection re-
agent in 100 μl IMDM. After 6 hrs incubation, 300 μl
of fresh IMDM/10%FCS containing 45 μg/ml gentami-
cin were added. Knockdown efficiency was assessed by
western blotting after 72 hrs. Pre-designed, chemically-
modified, siRNA oligoribonucleotides (Stealth™) target-
ing ID2 or ID3, as well as a negative control (Stealth™
medium GC Duplex) were purchased from Invitrogen
(Carlsbad, CA, USA). The sequences of the ID siRNAs
were as follows:
ID2: 5’- ACGTCATCGACTACATCTTGGACCT-3’;
ID3: 5’- GGCACTCAGCTTAGCCAGGTGGAAA-3’Cell viability assay
Cell viability was assessed using the 3-(4,5-dimethilthia-
zol-2yl)-2,5-diphenyl tetrazolium bromide (MTT) assay.
MEC1 cells were incubated with 0.5 mg/ml MTT for
2 hrs at 37°C, 5% CO2, while primary CLL cells required
4 hrs of incubation. Cells were then harvested and recov-
ered by centrifugation and incubated in 100–200 μl
dimethylsulphoxide at 37°C for 20 minutes before optical
density was recorded in a microplate spectrophotometer at
560 nm. The percentage of cell viability assessed by MTT
assay was used to determine IC50 concentrations from
dose–response curves at 72 hrs following treatment with 4
different drug concentrations.Western blotting
Cells were lysed, electrophoresed on polyacrylamide
(15%)-SDS gels followed by western blotting, essentially
as described previously [62]. After incubation with pri-
mary rabbit polyclonal antibodies against either ID2 (sc-
489) or ID3 (sc-490) (Santa Cruz Biotechnology, Dallas,
TX, USA), membranes were washed in 0.05% Tween-20
in TBS and incubated for 1 hr with polyclonal goat
horseradish peroxidase–conjugated secondary antibody
(AbCam, Cambridge, UK). Following extensive washes,
bound antibodies were visualized by enhanced chemilu-
minescence (ECL, Millipore, Billerica, MA, USA) on X-
ray films. Membranes were then stripped by incubation
with stripping buffer (25 mM glycine pH2, 1% SDS) for
30 minutes, washed and reprobed with primary rabbit
polyclonal antibody against GAPDH (Sigma-Aldrich),
followed by secondary antibody detection as described
above. Protein bands on western blot films were quanti-
fied by densitometric scanning and analysis using ‘Ima-
geJ’ software. Heatmap images were created using the
‘HeatMapViewer’ module in the GenePattern software
suite [56].
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For MTT assay data, continuous variables were compared
using the Student’s t-test while correlation between con-
tinuous variables was performed by determination of Pear-
son’s correlation coefficient using the ‘VassarStats’ online
statistical calculator [63]. All statistical tests were two-sided.
Boxplots were generated by using the ‘BoxPlotR’ online tool
[64]. Statistical analysis of gene overlap by hypergeometric
distribution was performed using the ‘phyper’ algorithm in
Bioconductor R.Additional files
Additional file 1: Figure S1. Kaplan-Meier plots showing the relation
between ID3 expression and clinical outcome in CLL. A: analysis of time
to first treatment for GSE39671 dataset; B: analysis of time to first
treatment for GSE22762 dataset; C: analysis of survival time for GSE22762
dataset. For each dataset, patients were grouped according to high (red
line) and low (blue line) ID3 expression. The significance of the difference
in clinical end-point between high and low ID3 expression patient groups
was determined by log rank test.
Additional file 2: Figure S2. Performance of consensus clustering
showing optimum partitioning of seven CLL sub-types. A: Delta area plot
showing increase in area under the consensus cumulative distribution
function for different numbers of sub-groups (‘k’ on x axis); B: Heatmap
representation of the consensus matrix for k = 7 sub-groups.
Additional file 3: Table S1. KEGG pathway enrichment for molecular
sub-types identified by consensus clustering. The top 20 pathways
that significantly overlap with the gene signature defining each of the
7 molecular sub-type (cluster groups – clu) are shown.
Additional file 4: Table S2. Oncogenic signature enrichment for
molecular sub-types identified by consensus clustering. The top 20
oncogenic signatures that significantly overlap with the gene signatures
defining each of the 7 molecular sub-type (cluster groups – clu) are
shown.
Additional file 5: Table S3. MIC scores and other metrics from
MINE investigation of ID2/ID3-coupled genes in CLL. Gene symbols
that are common between the ID2 and ID3 lists are highlighted
in yellow.
Additional file 6: Table S4. Gene Ontology and pathway enrichment
analysis of ID2 and ID3 candidate targets inferred from MIC analysis. Only
the top-ranked 25 Gene Ontology terms for biological process are shown.
Pathways that are common to both ID2 and ID3 MIC-inferred targets are
highlighted in yellow.
Additional file 7: Table S5. Description of CLL patient characteristics.
Additional file 8: Figure S3. Original scanned images of western blot
analysis of ID protein expression levels in primary CLL. The images shown
were used to compile Figure 5A in the main manuscript. The order of
CLL samples in the left and right-hand panels corresponds to that in
Figure 5A. An indicative size marker scale in kDa is shown together with
identities of the 36 kDa GAPDH and ID2/ID3 protein bands. The latter
were verified in independent siRNA knock-down and transfection-over-
expression experiments. Note that only the relevant sections of blots
were re-probed with antibody for GAPDH.
Additional file 9: Figure S4. Quantification of western blot analysis of
ID protein expression levels in primary CLL. Band intensities of the
western data shown in Figure 5A were quantified by densitometric
scanning using ‘ImageJ’ software. Data for raw band intensities is shown.
Normalised band intensity data is presented in Figure 5B of the main
manuscript.
Additional file 10: Figure S5. Original scanned images of western blot
analysis of ID protein expression in siRNA knock-down experiments. The
images shown were used to compile Figure 10A&C in the mainmanuscript. The order of samples for the analysis of MEC1 cells is the
same as in Figure 10. An indicative size marker scale in kDa is shown
together with identities of the 36 kDa GAPDH and ID2/ID3 protein bands.
The latter were verified in independent siRNA knock-down and
transfection-over-expression experiments. Note that only the relevant
sections of blots were re-probed with antibody for GAPDH.
Additional file 11: Figure S6. Original scanned images of western blot
analysis of ID protein expression in HUVEC co-culture experiments. The
images shown in panels A-D were used to compile Figure 12 in the main
manuscript. The order of CLL samples in each panel (A-D) corresponds to
that in Figure 12. An indicative size marker scale in kDa is shown together
with identities of the 36 kDa GAPDH and ID2/ID3 protein bands. The
latter were verified in independent siRNA knock-down and transfection-
over-expression experiments. Note that only the relevant sections of blots
were re-probed with antibody for GAPDH.
Additional file 12: Figure S7. Quantification of western blot analysis of
ID protein expression levels in CLL cells following manipulation of
intracellular GSH levels. Band intensities of the western data shown in
Figure 12 of the main manuscript were quantified by densitometric
scanning using ‘ImageJ’ software. Data were normalized to the GAPDH
loading control and, for each ID protein, expressed as fold-change
(relative band intensity) relative to the uncultured control (T0).
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